Botulism Immune Globulin Intravenous (Human) – BabyBIG®
Revision Date: September 17, 2018

Rationale for Update:
• Updated process to access product.

Please consult the Product Prescribing Information1 for further information about this product.

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Baxalta Inc. Weslake Village, California. Distributed for Infant Botulism Treatment and Prevention Program, California Department of Public Health.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Authorization and access</td>
<td>This product is not stocked in the Provincial Vaccine Depot, therefore, special authorization and access procedures must be followed: Infant Botulism Immune Globulin Intravenous (Baby-IV®) use must be approved and accessed via the Zone Medical Officer of Health (MOH). Refer to: Public Health Notifiable Disease Management Guidelines. <a href="http://www.health.alberta.ca/professionals/notifiable-diseases-guide.html">www.health.alberta.ca/professionals/notifiable-diseases-guide.html</a></td>
</tr>
</tbody>
</table>
| Indications for use of botulism immune globulin | Treatment of infant botulism caused by toxin types A or B
• Administer as soon as clinical diagnosis of infant botulism is made.
• Use for infants younger than one year of age.
For further information about the disease and reporting requirements refer to the Public Health Notifiable Disease Management Guidelines – Botulism.2 |
| Dose | Refer to: Product Prescribing Information1
Note: This is a treatment product administered under the direction of a physician in an acute care setting. |
| Route | Intravenous infusion Refer to: Product Prescribing Information1 |
| Schedule | Refer to: Product Prescribing Information1 |

References